United Therapeutics Corporation $UTHR is Renaissance Technologies LLC’s Largest Position

Renaissance Technologies LLC reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 6.4% during the first quarter, HoldingsChannel reports. The firm owned 1,787,019 shares of the biotechnology company’s stock after selling 122,240 shares during the period. United Therapeutics comprises about 1.7% of Renaissance Technologies LLC’s portfolio, making the stock its biggest holding. Renaissance Technologies LLC’s holdings in United Therapeutics were worth $1,059,667,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. Torren Management LLC purchased a new position in United Therapeutics in the 4th quarter worth approximately $26,000. Activest Wealth Management lifted its stake in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the last quarter. Entrust Financial LLC bought a new stake in United Therapeutics during the fourth quarter worth about $31,000. International Assets Investment Management LLC boosted its holdings in shares of United Therapeutics by 426.7% in the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 64 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB boosted its holdings in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $578.58, for a total transaction of $5,785,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,921,276.08. This trade represents a 34.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last three months, insiders have sold 513,333 shares of company stock valued at $286,933,042. 8.60% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts have commented on UTHR shares. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Raymond James Financial initiated coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $575.00 to $735.00 in a report on Thursday, May 7th. JPMorgan Chase & Co. lifted their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Royal Bank Of Canada upped their price target on shares of United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $648.33.

United Therapeutics Trading Down 0.2%

Shares of United Therapeutics stock opened at $528.47 on Friday. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The company has a market cap of $22.43 billion, a P/E ratio of 19.51, a PEG ratio of 1.77 and a beta of 0.58. The company’s fifty day simple moving average is $547.88 and its two-hundred day simple moving average is $531.39.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same period in the prior year, the business posted $6.63 earnings per share. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. Analysts predict that United Therapeutics Corporation will post 26.63 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.